Medical Pharmacology: Chapter 30 — Thyroid Pharmacology -- Module 4 — Radioiodine, Thyroid Cancer Pharmacotherapy, and Special Contexts

Chapter 30 — Thyroid Pharmacology — Module 4 — Radioiodine, Thyroid Cancer Pharmacotherapy, and Special Contexts
Tier: T3 (Clinical Vignette)

1. A 38-year-old woman with low-risk papillary thyroid cancer undergoes total thyroidectomy. She is scheduled for radioactive iodine (RAI) remnant ablation prepared by thyroid hormone withdrawal. Levothyroxine was held for 4 weeks. On the day of planned RAI administration, her serum TSH is 28 mIU/L. She is symptomatic with fatigue, cold intolerance, and mild cognitive slowing. Her nuclear medicine physician asks whether to proceed with RAI or postpone. Which of the following is the most appropriate management?

A) Postpone RAI and continue withdrawal for an additional 2 weeks, because TSH below 30 mIU/L is inadequate for NIS stimulation and proceeding would result in failed ablation; a TSH above 50 mIU/L is required for acceptable ablation rates with thyroid hormone withdrawal.
B) Proceed with RAI immediately and double the planned I-131 activity to compensate for suboptimal TSH stimulation, because increasing the administered activity can overcome the reduced NIS expression resulting from TSH below the optimal threshold.
C) Proceed with RAI as planned, because TSH of 28 mIU/L does not meet the threshold of 30 mIU/L but is sufficiently close in a symptomatic hypothyroid patient that the nuclear medicine team may proceed; alternatively, abandon withdrawal and administer rhTSH now to achieve a higher and more rapid TSH peak while allowing the patient to return to euthyroidism.
D) Proceed with RAI immediately because a TSH of 28 mIU/L is well above the required threshold of 30 mIU/L and represents fully adequate NIS stimulation for remnant ablation in this low-risk patient.
E) Administer intravenous liothyronine (T3) to acutely suppress the patient's symptoms of hypothyroidism before proceeding with RAI, because treating the withdrawal symptoms does not affect TSH levels and will not compromise ablation efficacy.

ANSWER: C

Rationale:

This question asked you to apply the TSH threshold requirement for RAI and reason through management when the withdrawal-achieved TSH is borderline. Option C is correct. The established threshold for adequate TSH stimulation before RAI is above 30 mIU/L, as NIS transcription is TSH-dependent and this level ensures adequate radioiodine uptake in remnant and metastatic thyroid tissue. This patient's TSH of 28 mIU/L is just below the threshold. The clinically sound response is to recognize this as borderline-inadequate and to consider the options: continuing withdrawal further to achieve TSH above 30 mIU/L (which will worsen the patient's symptomatic hypothyroidism), or switching to the rhTSH protocol — administering thyrotropin alfa 0.9 mg IM on two consecutive days, then RAI on day 3 — which would both achieve a higher TSH peak (typically above 100 mIU/L) and allow the patient to resume levothyroxine, resolving her withdrawal symptoms. For a low-risk patient where both methods are approved and equivalent in efficacy, the rhTSH approach is particularly advantageous at this juncture.

Option A: Option A is incorrect: a TSH above 50 mIU/L is not required for acceptable ablation rates; the established threshold is above 30 mIU/L, and TSH levels above 30 mIU/L achieved by withdrawal are associated with adequate ablation success; extending withdrawal for two additional weeks would worsen symptoms without a pharmacological basis for requiring TSH above 50 mIU/L.
Option B: Option B is incorrect: increasing the administered I-131 activity does not compensate for suboptimal NIS stimulation; NIS expression is TSH-dependent, and insufficient TSH produces reduced transporter expression regardless of how much I-131 is administered; increasing activity in this context would increase systemic radiation exposure without improving ablation of under-stimulated tissue.
Option D: Option D is incorrect: TSH of 28 mIU/L does not meet the 30 mIU/L threshold; it is below the required level, not above it; proceeding without addressing the borderline TSH is not the optimal management in a planned elective ablation.
Option E: Option E is incorrect: administering liothyronine (T3) before RAI would suppress TSH by providing exogenous thyroid hormone, which would dramatically worsen NIS stimulation; any exogenous thyroid hormone given before RAI abolishes the TSH elevation required for uptake and would make the RAI ineffective.

2. A 67-year-old man with RAI-refractory DTC has been on lenvatinib for 8 months with good radiographic response. He presents to the emergency department with acute appendicitis requiring urgent appendectomy. His last lenvatinib dose was taken this morning. The surgical team asks the oncologist whether lenvatinib poses any peri-operative risk and whether it should be held. Which of the following best describes the peri-operative management of lenvatinib?

A) Lenvatinib does not require peri-operative dose modification because its anti-tumor activity is limited to thyroid cancer cells and does not affect wound healing in normal tissues; the appendectomy can proceed without any adjustment to the lenvatinib schedule.
B) Lenvatinib should be continued through surgery but the dose reduced by 50% for 2 weeks postoperatively, because its VEGFR inhibition reduces systemic vascular resistance and lowering the dose mitigates intraoperative hypotension risk without fully interrupting anti-tumor therapy.
C) Lenvatinib should be held for 24 hours before surgery and resumed 24 hours after wound closure, because its half-life of approximately 28 hours means that a 48-hour interruption window achieves near-complete drug clearance sufficient to eliminate wound healing risk.
D) Lenvatinib should be held for at least 2 weeks before any elective surgery, and for urgent surgery should be held as soon as possible; however, because this is an emergency procedure that cannot be safely delayed, the drug is held after surgery and resumed only when wound healing is confirmed — typically at 7-10 days postoperatively depending on the wound integrity assessment.
E) Lenvatinib and all VEGFR inhibitors carry a risk of impaired wound healing and fistula formation because VEGF signaling is essential for angiogenesis in the healing wound bed; the standard recommendation is to hold VEGFR inhibitors at least 7-10 days before elective surgery and to withhold resumption until adequate wound healing is confirmed — for this urgent case, the drug should be held immediately and the surgical team informed of the fistula and healing risk.

ANSWER: E

Rationale:

This question asked you to apply the wound healing and fistula risk associated with VEGFR inhibitors to a peri-operative clinical scenario. Option E is correct. VEGF (vascular endothelial growth factor) signaling is essential not only for tumor angiogenesis but also for physiological wound healing — VEGF promotes the angiogenic response that allows granulation tissue formation and wound closure. VEGFR inhibitors including lenvatinib impair this physiological healing process, creating risk of delayed wound healing, wound dehiscence, and fistula formation. The standard peri-operative recommendation is to hold VEGFR inhibitors at least 7-10 days before elective procedures to allow partial drug clearance and restoration of VEGF-dependent wound healing capacity, and to withhold resumption until wound integrity is confirmed at the post-operative assessment. For this urgent case where surgery cannot be delayed, the drug should be held immediately at presentation and the surgical and anesthesia teams informed of the elevated wound complications risk, including fistula formation — a recognized serious complication that requires specific surveillance in the post-operative period.

Option A: Option A is incorrect: VEGFR inhibition by lenvatinib impairs wound healing in all tissues, not just tumor cells; the anti-angiogenic mechanism that reduces tumor blood supply also reduces the angiogenic response in healing surgical wounds; no dose modification is not an acceptable approach.
Option B: Option B is incorrect: reducing the dose does not adequately mitigate wound healing impairment; the mechanism of impaired healing is VEGFR inhibition itself, and partial VEGFR inhibition from a reduced dose still disrupts the VEGF-dependent healing response; the correct approach is drug interruption, not dose reduction.
Option C: Option C is incorrect: a 24-hour hold does not achieve meaningful drug clearance for lenvatinib; while lenvatinib's half-life is approximately 28 hours, one half-life eliminates only 50% of the drug, leaving substantial VEGFR inhibition; 7-10 days represents the established clinical standard for pre-operative holding — not 24 hours.
Option D: Option D is incorrect: while it correctly identifies that the drug should be held as soon as possible for urgent surgery and withheld until wound healing is confirmed postoperatively, the 2-week pre-operative hold requirement applies to elective procedures; the more important correct element — drug hold plus post-operative wound healing assessment before resumption — is captured more completely and accurately in option E, which also correctly names the specific risks (fistula formation) and the 7-10 day wound assessment window.

3. A 29-year-old woman at 8 weeks gestation presents with palpitations, tremor, and weight loss of 4 kg over 6 weeks. Examination reveals a diffuse goiter and mild proptosis. Serum TSH is 0.03 mIU/L, free T4 is 2.8 ng/dL (elevated), and TRAb (TSH receptor antibody) is positive at 6.2 times the upper reference limit. She has no prior thyroid history. What is the correct diagnosis and first-line pharmacological management?

A) This presentation is consistent with true Graves disease in pregnancy — confirmed by positive TRAb, diffuse goiter, proptosis, and free T4 substantially elevated above the upper third of the normal range — and requires antithyroid drug therapy with propylthiouracil (PTU) as the first-line agent in the first trimester, targeting maternal free T4 in the upper third of the normal reference range using the lowest effective dose.
B) This presentation is consistent with gestational transient thyrotoxicosis (GTT) caused by hCG stimulation; TRAb can be transiently positive in early pregnancy due to hCG cross-reactivity with the TSH receptor assay; no antithyroid drug treatment is needed and the patient should be reassured that the condition will resolve by 14-20 weeks.
C) This presentation requires methimazole (MMI) as first-line therapy because MMI achieves more rapid TSH receptor antibody (TRAb) titer reduction than PTU and is the preferred first-line agent for Graves disease in all trimesters of pregnancy, including the first trimester.
D) This presentation requires immediate high-dose PTU (600 mg loading dose followed by 200 mg every 8 hours) because the markedly elevated TRAb and severely suppressed TSH indicate impending thyroid storm in pregnancy, which carries a maternal mortality risk above 20% if not treated aggressively within the first 24 hours.
E) This presentation does not require treatment because proptosis and goiter are normal variants of the physiological thyroid enlargement and increased thyroid vascularity seen in all pregnant women due to hCG stimulation; the TRAb result should be repeated at 16 weeks before initiating any pharmacological intervention.

ANSWER: A

Rationale:

This question asked you to distinguish true Graves disease from gestational transient thyrotoxicosis (GTT) in the first trimester and identify the correct treatment. Option A is correct. This patient has true Graves disease in pregnancy, not GTT. The distinguishing features are unambiguous: a diffuse goiter, proptosis (periorbital changes reflecting thyroid-associated orbitopathy), markedly positive TRAb at 6.2 times the upper reference limit, and free T4 substantially elevated — none of which are features of physiological GTT. GTT is characterized by mild TSH suppression, mildly elevated free T4 without significant clinical orbitopathy or palpable goiter, negative TRAb, and spontaneous resolution by 14-20 weeks. True Graves disease in pregnancy requires antithyroid drug therapy to prevent maternal thyrotoxicosis complications (preterm delivery, growth restriction, cardiac failure) and fetal thyrotoxicosis from TRAb transfer. PTU is the correct first-line agent in the first trimester because MMI carries the risk of MMI embryopathy — a syndrome of aplasia cutis, choanal atresia, and esophageal atresia linked to first-trimester MMI exposure during organogenesis. The dosing target is maternal free T4 in the upper third of the normal reference range using the lowest effective PTU dose.

Option B: Option B is incorrect: TRAb positivity in early pregnancy is not a false positive from hCG cross-reactivity; TRAb assays are specific for TSH receptor antibodies, not hCG; the combination of positive TRAb, diffuse goiter, proptosis, and markedly elevated free T4 confirms true autoimmune Graves disease requiring treatment.
Option C: Option C is incorrect: MMI is specifically avoided in the first trimester because of the MMI embryopathy risk during organogenesis (approximately weeks 6-10); PTU is the first-trimester agent of choice, with a planned switch back to MMI after 16 weeks.
Option D: Option D is incorrect: while this patient has significant thyrotoxicosis requiring prompt treatment, the presentation described — even with markedly elevated TRAb and suppressed TSH — does not indicate thyroid storm, which requires additional features such as fever, tachyarrhythmia with hemodynamic compromise, altered mental status, or congestive heart failure; standard first-trimester Graves management with PTU at therapeutic doses is appropriate, not a loading-dose thyroid storm protocol.
Option E: Option E is incorrect: proptosis is not a normal variant of pregnancy; it is a specific feature of Graves orbitopathy, an autoimmune process that identifies this as true Graves disease; dismissing proptosis and a markedly positive TRAb as physiological findings would result in dangerous delay of necessary treatment.

4. A 72-year-old man has been on amiodarone 200 mg/day for ventricular arrhythmia for 3 years. He presents with a 6-week history of palpitations, heat intolerance, and 5 kg weight loss. TSH is undetectable, free T4 is 4.1 ng/dL (markedly elevated). Thyroid ultrasound performed today shows a structurally normal-appearing gland with absent vascularity on color Doppler. A thyroid ultrasound from 2 years ago showed a normal gland with normal vascularity. Serum IL-6 is 48 pg/mL (markedly elevated; reference <7 pg/mL). TRAb is negative. His cardiologist asks whether amiodarone should be discontinued and which antithyroid treatment should be started. What is the correct classification and treatment approach?

A) This presentation is consistent with type 1 amiodarone-induced thyrotoxicosis (AIT1); methimazole 40-60 mg/day should be initiated along with potassium perchlorate to reduce the intrathyroidal iodine load driving autonomous hormone synthesis; amiodarone may continue if discontinuation would pose significant arrhythmia risk.
B) This presentation is consistent with type 2 amiodarone-induced thyrotoxicosis (AIT2) — confirmed by absent Doppler vascularity reflecting avascular destructive thyroiditis, a previously normal gland, and markedly elevated IL-6; treatment is oral prednisone 40-60 mg/day tapered over approximately 3 months; amiodarone continuation versus discontinuation is a joint cardiology-endocrinology decision and should not be mandated by the endocrinologist alone.
C) The diagnosis cannot be established without radioiodine uptake scanning; amiodarone should be discontinued immediately in all patients with AIT because thyroid effects cannot be managed while the drug is continued; antithyroid treatment should be withheld until the uptake scan confirms the AIT type.
D) This presentation is consistent with type 2 AIT; however, glucocorticoids are contraindicated in a 72-year-old patient with ventricular arrhythmia because prednisone causes QT prolongation and will interact with amiodarone's class III antiarrhythmic effects; methimazole should be used instead despite its reduced efficacy in type 2 AIT.
E) This presentation is consistent with type 2 AIT; treatment is methimazole 40-60 mg/day because methimazole is the standard first-line agent for all forms of AIT regardless of type, and prednisone is reserved only for patients who fail methimazole after 6-8 weeks of therapy.

ANSWER: B

Rationale:

This question asked you to classify AIT type using the Doppler, IL-6, and structural findings, and to identify the correct treatment and shared decision-making approach. Option B is correct. This patient has type 2 AIT. The diagnostic features are unambiguous: absent vascularity on color Doppler (the hallmark of avascular destructive thyroiditis, consistent with type 2), a previously structurally normal gland (ruling out the pre-existing thyroid autonomy required for type 1), negative TRAb (excluding Graves disease), and markedly elevated IL-6 reflecting the intense inflammatory destructive process of type 2. Type 2 AIT is caused by the direct cytotoxic effects of amiodarone and desethylamiodarone on follicular cells, releasing preformed hormone without new synthesis. Because there is no ongoing new synthesis, antithyroid drugs that block synthesis (methimazole, PTU) are ineffective. Prednisone 40-60 mg/day tapered over approximately 3 months is the correct treatment, targeting the inflammatory destructive process. Regarding amiodarone continuation: this is explicitly a joint cardiology-endocrinology decision; in a patient with ventricular arrhythmia where amiodarone may be the only effective antiarrhythmic, discontinuation may not be appropriate, and type 2 AIT can be treated while the drug continues.

Option A: Option A is incorrect: the clinical picture is clearly type 2 AIT, not type 1 — absent Doppler vascularity and a previously normal gland are diagnostic of type 2; methimazole and potassium perchlorate are the type 1 regimen and are not appropriate for type 2.
Option C: Option C is incorrect: radioiodine uptake scanning is not required for diagnosis of AIT type when color Doppler and clinical findings are diagnostic; and RAI uptake scanning is routinely suppressed in both AIT types due to amiodarone's iodine loading, making it non-discriminatory; immediate amiodarone discontinuation in all AIT patients is also incorrect.
Option D: Option D is incorrect: glucocorticoids are not contraindicated in elderly patients with cardiac disease on amiodarone; prednisone does not cause clinically significant QT prolongation and does not interact with amiodarone's class III mechanism in a way that contraindicates its use; the clinical need for treating type 2 AIT with prednisone is not negated by age or amiodarone co-administration.
Option E: Option E is incorrect: methimazole is not effective for type 2 AIT — it blocks thyroid hormone synthesis, which is not the mechanism of thyrotoxicosis in type 2 (destructive release of preformed hormone); prednisone is first-line for type 2 AIT, not a second-line agent reserved for methimazole failure.

5. A 70-year-old man with low-risk DTC diagnosed 4 years ago underwent total thyroidectomy and RAI ablation. He has been maintained on suppressive levothyroxine with TSH 0.08 mIU/L. His most recent annual follow-up at 3 years showed excellent response — undetectable stimulated thyroglobulin, negative anti-thyroglobulin antibodies, negative imaging. He presents today after his primary care physician discovered paroxysmal atrial fibrillation on a 48-hour Holter monitor obtained for evaluation of intermittent palpitations. His CHA₂DS₂-VASc score is 3. What is the most appropriate endocrinological management in response to this finding?

A) Maintain TSH suppression at 0.08 mIU/L and manage the atrial fibrillation with rate control and anticoagulation alone, because changing the levothyroxine dose during atrial fibrillation management risks thyroid hormone fluctuations that could precipitate thyroid storm.
B) Increase the levothyroxine dose to achieve deeper TSH suppression below 0.01 mIU/L, because atrial fibrillation in a DTC patient indicates that the cancer is producing ectopic TSH and deeper suppression is required to counter this autonomous TSH source.
C) Immediately discontinue levothyroxine and refer the patient for thyroid hormone withdrawal, because the new atrial fibrillation is an absolute contraindication to any levothyroxine therapy in patients over 65 regardless of thyroid cancer history.
D) De-escalate levothyroxine to target TSH in the standard replacement range of 0.5-2.0 mIU/L, because this patient has achieved excellent response and reclassifies to low functional risk — the oncological justification for TSH suppression below 0.5 mIU/L no longer exists — and the sustained subclinical thyrotoxicosis from TSH below 0.1 mIU/L is a recognized contributor to atrial fibrillation risk in older patients; anticoagulation based on CHA₂DS₂-VASc score should be managed in parallel with cardiology.
E) Refer the patient for radiofrequency ablation of the atrial fibrillation foci before addressing the levothyroxine dose, because rhythm control with catheter ablation is the preferred first-line management of paroxysmal AF in patients with DTC and TSH modification should be deferred until after successful AF ablation.

ANSWER: D

Rationale:

This question asked you to integrate ATA response-to-therapy reclassification with the cardiovascular risk of TSH suppression in an older patient with new AF. Option D is correct. This patient presents the ideal scenario for applying the ATA dynamic reclassification system. He has confirmed excellent response at 3 years — undetectable stimulated thyroglobulin, negative antibodies, negative imaging — which reclassifies him from his initial low-risk category to a low functional risk category where the appropriate TSH target is the standard replacement range of 0.5-2.0 mIU/L. His current TSH of 0.08 mIU/L represents ongoing mild TSH suppression that is no longer oncologically justified given his disease-free status. Sustained subclinical thyrotoxicosis from TSH below 0.1 mIU/L in a 70-year-old man is a recognized contributor to the two-to-threefold increased AF risk associated with TSH suppression in older patients. De-escalating levothyroxine to target replacement-range TSH removes the subclinical thyrotoxicosis, reduces the chronotropic and electrophysiological substrate for AF, and is consistent with guideline-directed oncological management. Anticoagulation based on CHA₂DS₂-VASc score of 3 is independently indicated and should be co-managed with cardiology.

Option A: Option A is incorrect: maintaining TSH at 0.08 mIU/L in a patient with confirmed excellent response and new AF continues unnecessary cardiovascular risk; changing levothyroxine dose to the replacement range does not cause thyroid hormone fluctuations sufficient to precipitate thyroid storm, which requires massive thyroid hormone excess, not dose de-escalation.
Option B: Option B is incorrect: deepening TSH suppression would worsen the AF substrate by intensifying subclinical thyrotoxicosis; atrial fibrillation in a DTC patient on suppressive therapy is not a sign of ectopic TSH production — it is a recognized adverse effect of the suppressive therapy itself.
Option C: Option C is incorrect: levothyroxine cannot be discontinued in a thyroidectomized patient without inducing severe hypothyroidism; the goal is TSH target adjustment to the replacement range, not drug withdrawal; new AF is not an absolute contraindication to levothyroxine therapy.
Option E: Option E is incorrect: while rhythm control with catheter ablation may be an appropriate long-term option for paroxysmal AF management, deferring the levothyroxine adjustment until after ablation is not appropriate — removing the subclinical thyrotoxicosis addresses a potentially modifiable contributor to the AF and is consistent with current oncological management guidelines; this adjustment should not wait.

6. A 3-year-old girl is found to carry a germline RET codon 634 mutation (cysteine-to-arginine substitution) after her father is diagnosed with medullary thyroid cancer as part of MEN2A (multiple endocrine neoplasia type 2A). She has no symptoms. Serum calcitonin is normal for age. Ultrasound of the neck shows no thyroid abnormality. Her parents ask when prophylactic thyroidectomy should be performed. Which of the following best describes the risk-stratified timing recommendation for this child?

A) Prophylactic thyroidectomy should be deferred until calcitonin becomes elevated, because a normal calcitonin in a 3-year-old indicates that MTC has not yet developed, and operating before biochemical evidence of disease exposes the child to unnecessary surgical risk in a condition with high cure rates when detected early.
B) Prophylactic thyroidectomy should be deferred until age 18, because performing thyroidectomy in a 3-year-old carries a higher rate of permanent hypoparathyroidism and recurrent laryngeal nerve injury than surgery in adults, and the MTC risk from codon 634 does not manifest until adulthood.
C) Codon 634 is classified as a high-risk RET mutation associated with early MTC onset — typically before age 5 — and ATA guidelines recommend prophylactic thyroidectomy before age 5 in children with this mutation; the current normal calcitonin and negative imaging support proceeding with surgery in the near term while curative resection is still feasible.
D) Prophylactic thyroidectomy is not recommended for children with codon 634 mutations because this codon is associated with primary hyperparathyroidism and pheochromocytoma in MEN2A but not with a meaningful MTC risk before adulthood; surveillance with annual calcitonin measurement is sufficient until age 21.
E) Prophylactic thyroidectomy should be performed within the next 6 months regardless of calcitonin level because codon 634 mutations in MEN2A carry a greater than 90% lifetime penetrance of MTC and a normal calcitonin at age 3 does not exclude microscopic C-cell hyperplasia that will progress to invasive MTC before school age in most children.

ANSWER: C

Rationale:

This question asked you to apply ATA RET codon-based risk stratification to determine the appropriate timing for prophylactic thyroidectomy in a young child. Option C is correct. The ATA risk stratification system classifies RET codon mutations into three tiers based on their association with MTC aggressiveness and age of onset. Codon 634 mutations — the most common MEN2A mutation — are classified as high-risk (ATA category C/high risk), associated with MTC that typically develops before age 5-10 in some kindreds. ATA guidelines recommend prophylactic thyroidectomy before age 5 for children with this codon mutation, and in the presence of normal calcitonin and negative imaging, curative thyroidectomy is still highly feasible. The normal calcitonin is reassuring that surgery at this point is likely curative, which supports proceeding in the near term rather than deferring.

Option A: Option A is incorrect: deferring surgery until calcitonin elevation means waiting for biochemical evidence that MTC has already developed; the purpose of prophylactic thyroidectomy is to operate before MTC arises, not after; codon 634 MTC can develop in children before age 5, making calcitonin-triggered surgery potentially too late for curative intent.
Option B: Option B is incorrect: codon 634 mutations are not safely deferred to age 18; the high-risk classification reflects documented MTC development in children and young adolescents; deferral to adulthood would expose the child to a high probability of developing MTC that could become metastatic before the intervention window closes.
Option D: Option D is incorrect: codon 634 is strongly associated with MTC risk in MEN2A — it is one of the canonical high-risk mutations; while codon 634 is also associated with pheochromocytoma and hyperparathyroidism, the MTC risk is the primary reason for prophylactic thyroidectomy and is emphatically not absent before adulthood.
Option E: Option E is incorrect: while codon 634 does carry high lifetime MTC penetrance, the recommendation is before age 5, not within 6 months from this specific presentation; and the qualifier "regardless of calcitonin level" overstates urgency — a normal calcitonin in this age group is compatible with normal C-cell development and the timing of surgery in the near term (before age 5) is appropriate, not emergency surgery within 6 months.

7. A neonate is brought to the pediatric emergency department on day 7 of life with a 2-day history of persistent tachycardia (heart rate 188 bpm), poor feeding, marked irritability, and a visibly enlarged neck. The mother has a history of Graves disease managed with PTU throughout pregnancy; she was euthyroid at delivery. Maternal TRAb measured at 28 weeks was 5.1 times the upper reference limit. The newborn screen TSH at 48 hours was reported as normal. Thyroid function tests today show TSH 0.02 mIU/L (suppressed) and free T4 5.8 ng/dL (markedly elevated). Which of the following represents the correct diagnosis and initial pharmacological management?

A) This is neonatal Graves disease presenting on day 7 as maternal PTU cleared from the neonatal circulation; the preferred antithyroid agent is methimazole (MMI) 0.2-0.5 mg/kg/day divided every 8 hours because PTU carries a significant hepatotoxicity risk in neonates; propranolol 0.5-2 mg/kg/day divided every 8 hours should be added for rate control and adrenergic symptom management.
B) This is neonatal Graves disease and the preferred antithyroid agent is PTU 5-10 mg/kg/day because PTU's additional peripheral T4-to-T3 conversion blockade via type 1 deiodinase inhibition provides faster reduction of circulating T3 and more rapid symptom control than methimazole in neonates with severe thyrotoxicosis.
C) The suppressed TSH and elevated free T4 on day 7 indicate that the normal 48-hour newborn screen was a false negative from the newborn screening laboratory; the condition is neonatal hypothyroidism caused by maternal PTU suppression of the neonatal pituitary, and treatment is levothyroxine supplementation rather than antithyroid drugs.
D) This is a normal physiological response to maternal Graves antibody clearance; a TSH of 0.02 mIU/L with elevated free T4 in the neonatal period reflects the declining maternal TRAb concentration and no pharmacological intervention is required; repeat thyroid function tests in 2 weeks will show normalization as antibodies clear.
E) This presentation requires urgent total thyroidectomy because TRAb above 3 times the upper reference limit with overt neonatal thyrotoxicosis unresponsive to neonatal antithyroid drugs represents a surgical emergency; medical management is only appropriate for mild neonatal Graves disease with TRAb below the 3-times threshold.

ANSWER: A

Rationale:

This question asked you to diagnose neonatal Graves disease presenting with delayed onset and to select the correct antithyroid agent given the neonatal-specific safety profile. Option A is correct. This neonate has classic delayed-onset neonatal Graves disease, presenting on day 7 as maternal PTU — which was protecting the neonatal thyroid by crossing the placenta and suppressing synthesis in utero — cleared from the neonatal circulation over the first 3-7 days of life. The unmasking of TRAb-driven thyroid stimulation produces the clinical picture: tachycardia at 188 bpm, poor feeding, irritability, goiter, suppressed TSH, and markedly elevated free T4. The mother's TRAb at 5.1 times the upper reference limit well exceeded the 3-times threshold that predicts significant neonatal risk, and the apparently reassuring 48-hour newborn screen reflected residual maternal PTU suppression, not absence of disease. Methimazole is the preferred antithyroid agent in neonates — PTU is specifically avoided in neonates and young children because of its significant hepatotoxicity risk including fulminant hepatic failure. Propranolol provides adrenergic symptom control while MMI establishes biochemical control over the following days to weeks. The course is self-limited as maternal TRAb titers decline over 3-6 months.

Option B: Option B is incorrect: PTU is specifically contraindicated in neonates due to hepatotoxicity risk; while PTU does inhibit D1 and reduce T4-to-T3 conversion, this pharmacological advantage does not outweigh the serious hepatic safety risk in neonates; MMI is the established preferred agent in this age group.
Option C: Option C is incorrect: the clinical picture — suppressed TSH and elevated free T4 — represents thyrotoxicosis (too much thyroid hormone), not hypothyroidism (too little); neonatal hypothyroidism from PTU suppression would produce an elevated TSH with low free T4, the opposite pattern; levothyroxine would be dangerous in this thyrotoxic neonate.
Option D: Option D is incorrect: a heart rate of 188 bpm, goiter, poor feeding, suppressed TSH, and free T4 at 5.8 ng/dL is not a normal physiological state or a mild self-resolving condition; untreated neonatal thyrotoxicosis at this severity carries risk of cardiac failure, advanced bone age causing premature craniosynostosis, and death; pharmacological management is urgently required.
Option E: Option E is incorrect: total thyroidectomy is not the treatment for neonatal Graves disease; neonatal Graves disease is pharmacologically managed and self-limited as maternal TRAb titers decline; surgery is not indicated regardless of initial TRAb titer, which reflects only the risk stratification for development of disease, not a surgical threshold.

8. A 59-year-old woman with RAI-refractory DTC has been on lenvatinib 24 mg/day for 5 months with partial radiographic response. She presents with blood pressure of 172/108 mmHg despite taking amlodipine 10 mg/day initiated 3 months ago, and urine dipstick shows 3+ proteinuria. Urine protein-to-creatinine ratio is 2.8 g/g (normal <0.2 g/g). Serum creatinine is stable. Which of the following best describes the appropriate management of these toxicities?

A) Lenvatinib should be permanently discontinued because the combination of uncontrolled hypertension and nephrotic-range proteinuria represents grade 4 combined organ toxicity that precludes safe continuation of VEGFR inhibitor therapy at any dose.
B) Lenvatinib should be continued at the current dose because hypertension and proteinuria are expected on-target VEGFR inhibition effects that confirm drug activity against the tumor; treating the toxicities with additional antihypertensives and proteinuria monitoring is the correct approach without dose modification.
C) Lenvatinib should be held until blood pressure normalizes below 140/90 mmHg, then resumed at the same dose because proteinuria in the absence of rising creatinine does not reflect true nephrotoxicity and does not require dose reduction.
D) Lenvatinib dose should be reduced to 14 mg/day and a second antihypertensive agent added to amlodipine; proteinuria at this level should be monitored with serial urine protein-to-creatinine ratios but does not independently require dose reduction if blood pressure can be controlled.
E) Both the grade 3 hypertension (uncontrolled despite antihypertensive therapy) and the significant proteinuria warrant lenvatinib dose reduction — the standard first dose reduction is from 24 mg to 20 mg/day; a second antihypertensive should be added for blood pressure management, and proteinuria should be monitored with serial urine protein-to-creatinine ratios; dose reduction addresses both toxicities simultaneously within the approved management algorithm.

ANSWER: E

Rationale:

This question asked you to apply the toxicity grading and dose reduction algorithm for lenvatinib to a patient with concurrent uncontrolled hypertension and significant proteinuria. Option E is correct. Lenvatinib's VEGFR inhibition impairs nitric oxide-mediated vascular tone (producing hypertension) and disrupts glomerular capillary integrity (producing proteinuria). Grade 3 hypertension — defined as requiring more than one antihypertensive agent to control blood pressure that remains elevated — is an indication for lenvatinib dose reduction when it cannot be controlled with antihypertensive optimization. The standard first dose reduction for lenvatinib is from 24 mg to 20 mg/day. The significant proteinuria at 2.8 g/g urine protein-to-creatinine ratio also warrants dose modification — nephrotic-range proteinuria (above 3.5 g/24h or equivalent) is an indication for lenvatinib interruption, and this patient is approaching that threshold. Adding a second antihypertensive agent (ACE inhibitor or ARB given their additional anti-proteinuric benefit through RAAS blockade) addresses both the blood pressure and proteinuria simultaneously. Serial urine protein monitoring guides further dose decisions.

Option A: Option A is incorrect: permanent discontinuation is not warranted at this stage; grade 3 toxicities managed with dose reduction and supportive care are within the approved management algorithm; dose reduction rather than discontinuation is the first step for grade 3 events that do not represent life-threatening organ failure.
Option B: Option B is incorrect: while on-target VEGFR effects do confirm drug activity, grade 3 hypertension uncontrolled on existing antihypertensive therapy and significant proteinuria require dose modification — continuing at full dose without modification exposes the patient to progressive renal and cardiovascular injury.
Option C: Option C is incorrect: holding the drug and resuming at the same dose does not address the dose-dependent mechanism of the toxicities; both hypertension and proteinuria are dose-related effects of VEGFR inhibition, and resuming at the same dose will re-precipitate the same toxicities.
Option D: Option D is incorrect: while dose reduction to 14 mg represents the second reduction level (the standard reductions are 24→20→14→10 mg), the first dose reduction step for grade 3 toxicity is to 20 mg, not 14 mg; jumping to the second reduction level without first attempting the 20 mg dose is not the standard algorithm; also, proteinuria at 2.8 g/g warrants independent consideration and monitoring, not dismissal as long as creatinine is stable.

9. A 34-year-old woman with a history of intermediate-risk DTC treated 4 years ago presents at 8 weeks gestation for her first prenatal visit. Her pre-pregnancy TSH target was 0.1-0.5 mIU/L based on her intermediate-risk classification, and her most recent TSH before conception was 0.38 mIU/L on levothyroxine 125 mcg/day. Today her TSH is 0.42 mIU/L and free T4 is within the normal range for the first trimester. She had confirmed excellent response to treatment at her 3-year follow-up. Which of the following best describes how her levothyroxine management should change during this pregnancy?

A) Her current TSH of 0.42 mIU/L is appropriately suppressed for an intermediate-risk DTC patient and her levothyroxine dose should remain unchanged throughout pregnancy, because ATA guidelines specify that DTC-related TSH targets supersede pregnancy-specific TSH adjustments at all disease risk levels.
B) Her levothyroxine dose will likely need to increase by 25-50% during pregnancy to compensate for increased thyroxine-binding globulin (TBG), expanded volume of distribution, and placental T4 deiodination — all of which reduce free T4 and raise TSH during pregnancy; thyroid function tests should be monitored every 4 weeks in the first trimester and every 6-8 weeks thereafter, with dose adjustments to maintain TSH within the pregnancy-normal reference range, which in the first trimester may be as low as 0.1 mIU/L.
C) Her levothyroxine dose should be reduced by 30% in the first trimester because hCG stimulation of the TSH receptor will augment thyroid activity even in a thyroidectomized patient, creating a risk of iatrogenic hyperthyroidism if the pre-pregnancy dose is continued unchanged.
D) Her levothyroxine dose should be increased to achieve TSH below 0.1 mIU/L throughout all three trimesters because the elevated hCG and estrogen of pregnancy independently stimulate residual thyroid tissue and require deeper suppression to maintain oncological control during the 9-month period when TSH monitoring is most challenging.
E) Because she achieved excellent response and the residual oncological risk is very low, levothyroxine should be discontinued at conception and resumed postpartum, allowing her to have a drug-free pregnancy; the fetal thyroid will supply all necessary thyroid hormone for both mother and fetus during gestation.

ANSWER: B

Rationale:

This question asked you to apply pregnancy-specific levothyroxine pharmacokinetics and TSH target adjustments to a DTC survivor with excellent response. Option B is correct. Pregnancy substantially increases levothyroxine requirements — typically by 25-50% — through three concurrent mechanisms: estrogen-driven increase in thyroxine-binding globulin (TBG) production, which sequesters additional T4 and reduces free T4; expanded plasma volume and volume of distribution; and placental type 3 deiodinase activity, which converts T4 to inactive reverse T3 and T3 to inactive T2, increasing thyroid hormone clearance. Together these mechanisms raise TSH as free T4 falls if the dose is not adjusted upward. This patient's TSH of 0.42 mIU/L is currently within her pre-pregnancy target; without dose adjustment, her TSH will likely rise as pregnancy progresses and TBG increases. Monthly first-trimester TFT monitoring with dose adjustments is the standard approach. The first-trimester TSH lower limit is approximately 0.1 mIU/L due to hCG stimulation, so a TSH of 0.1-2.5 mIU/L is generally acceptable in the first trimester depending on the guideline used. Given her excellent response history and low residual oncological risk, the pregnancy-normal TSH range is appropriate rather than continued aggressive suppression.

Option A: Option A is incorrect: ATA guidelines explicitly acknowledge that TSH targets in DTC survivors must be interpreted within pregnancy-specific reference ranges; dose adjustments are required, and the pre-pregnancy target is not held fixed throughout gestation.
Option C: Option C is incorrect: thyroidectomized patients do not have residual thyroid tissue responsive to hCG stimulation; hCG does not stimulate a gland that has been ablated; the levothyroxine dose typically needs to increase during pregnancy, not decrease, because pharmacokinetic changes reduce free T4 if the dose is unchanged.
Option D: Option D is incorrect: intensifying suppression to below 0.1 mIU/L throughout all three trimesters is not indicated for a patient with excellent response and low residual risk; such suppression would expose the patient to unnecessary cardiovascular and bone effects without meaningful oncological benefit.
Option E: Option E is incorrect: levothyroxine is essential for this thyroidectomized patient and cannot be discontinued; she has no functional thyroid tissue; discontinuation would cause severe maternal hypothyroidism, which is associated with miscarriage, preterm delivery, impaired fetal neurodevelopment, and placental abruption; the fetal thyroid does not supply thyroid hormone to the mother.

10. A 64-year-old woman with type 1 amiodarone-induced thyrotoxicosis (AIT1) has been on methimazole 60 mg/day for 6 weeks. Repeat thyroid function tests show TSH still undetectable and free T4 of 3.2 ng/dL — improved from 4.8 ng/dL at baseline but still markedly elevated. She has a pre-existing multinodular goiter and color Doppler confirms persistent hypervascularity. Amiodarone is being continued for refractory ventricular arrhythmia. Her endocrinologist is considering adding potassium perchlorate. Which of the following best describes the correct approach to potassium perchlorate augmentation, including its rationale and a critical safety limitation?

A) Potassium perchlorate should not be added because its mechanism — blocking iodide transport into the thyroid — is identical to that of methimazole, making combination therapy purely additive without clinical benefit; doubling the methimazole dose to 120 mg/day is the correct approach to inadequate type 1 AIT control.
B) Potassium perchlorate 200 mg four times daily should be added indefinitely as maintenance therapy alongside methimazole, because the continuous amiodarone iodine load requires ongoing NIS blockade for as long as the patient remains on amiodarone; there are no significant safety concerns with long-term perchlorate use.
C) Potassium perchlorate should be added at 100 mg twice daily — not 200 mg four times daily — because the lower dose achieves equivalent NIS blockade with a substantially reduced risk of aplastic anemia; the lower-dose regimen can be continued for up to 12 months safely.
D) Potassium perchlorate 200 mg four times daily should be added to methimazole to reduce the intrathyroidal iodine load driving autonomous synthesis in this iodine-saturated gland; however, potassium perchlorate use must be limited to approximately 4-6 weeks because prolonged use carries a risk of aplastic anemia — a rare but potentially fatal hematological toxicity — and its use should be time-limited rather than maintained indefinitely.
E) Potassium perchlorate is indicated only for type 2 AIT, not type 1, because it works by blocking the NIS-mediated release of preformed hormone from destructed follicles; in type 1 AIT, where the problem is ongoing synthesis rather than release, perchlorate has no pharmacological role.

ANSWER: D

Rationale:

This question asked you to apply the correct indication, dosing, and critical safety limitation of potassium perchlorate in refractory type 1 AIT. Option D is correct. Potassium perchlorate competitively blocks the sodium-iodide symporter (NIS), preventing new iodide from entering the thyroid gland and promoting gradual depletion of the intrathyroidal iodine pool that is fueling autonomous synthesis in type 1 AIT. Methimazole alone may be insufficient in type 1 AIT because the massive intrathyroidal iodine burden from amiodarone overwhelms the synthesis blockade; adding potassium perchlorate addresses the substrate-level problem directly. The correct dose is 200 mg four times daily. The critical safety limitation is the risk of aplastic anemia — a rare but potentially fatal idiosyncratic hematological toxicity that has been documented with prolonged potassium perchlorate use. This risk constrains its use to approximately 4-6 weeks, after which it should be discontinued regardless of thyroid status. In this patient who will continue amiodarone long-term, perchlorate provides a time-limited adjunct to achieve better thyroid control during the most refractory phase, not indefinite maintenance.

Option A: Option A is incorrect: potassium perchlorate and methimazole work through entirely different mechanisms — perchlorate blocks iodide transport (NIS blockade), while methimazole blocks iodide organification (TPO inhibition); they are mechanistically complementary and their combination provides two-level substrate control in type 1 AIT.
Option B: Option B is incorrect: potassium perchlorate cannot be used indefinitely because of aplastic anemia risk; long-term continuous use is contraindicated regardless of ongoing amiodarone exposure; the 4-6 week time limit is a hard safety constraint.
Option C: Option C is incorrect: the established dose for potassium perchlorate in AIT is 200 mg four times daily (800 mg/day total); there is no established evidence that 100 mg twice daily (200 mg/day total) achieves equivalent NIS blockade; the 4-6 week duration limit applies regardless of dose.
Option E: Option E is incorrect: potassium perchlorate is specifically indicated for type 1 AIT, not type 2; its mechanism — blocking iodide entry into the gland — directly addresses the iodine-substrate excess driving autonomous synthesis in type 1; in type 2 AIT, the thyroid is releasing preformed hormone from destructed cells and NIS is not the relevant target; perchlorate has no role in type 2.

11. A 31-year-old woman presents at 5 months postpartum with a 6-week history of progressive fatigue, weight gain of 4 kg, constipation, and cold intolerance. She recalls having palpitations around 6 weeks postpartum that resolved spontaneously and were not evaluated. She has no prior thyroid history. Anti-TPO antibody is strongly positive at 8 times the upper reference limit. TSH is 12.4 mIU/L. Free T4 is low-normal. She is not breastfeeding. She asks whether she will need lifelong thyroid medication. Which of the following best describes the diagnosis, treatment decision, and counseling regarding long-term thyroid risk?

A) This is the hypothyroid phase of postpartum thyroiditis — her spontaneous palpitations at 6 weeks postpartum represent the unrecognized hyperthyroid phase; levothyroxine should be initiated for symptomatic hypothyroidism and continued for 6-12 months, then tapered and discontinued with TSH monitoring to assess whether permanent hypothyroidism has developed; her strongly positive anti-TPO antibody identifies her as being in the approximately 25-30% who will develop permanent hypothyroidism and require lifelong levothyroxine.
B) This is primary autoimmune hypothyroidism (Hashimoto thyroiditis) unrelated to her recent delivery; the postpartum timing is coincidental; levothyroxine should be initiated and continued indefinitely because all women with TSH above 10 mIU/L and positive anti-TPO antibodies will require lifelong thyroid hormone replacement.
C) This is the hypothyroid phase of postpartum thyroiditis; levothyroxine should not be initiated because the hypothyroid phase is always self-limiting within 4 weeks; the patient should be reassured and re-tested in 4 weeks, at which point TSH will have normalized without treatment.
D) This is the hypothyroid phase of postpartum thyroiditis; however, levothyroxine is contraindicated because her strongly positive anti-TPO antibodies indicate active autoimmune thyroid inflammation and exogenous thyroid hormone would suppress TSH and eliminate the TSH-driven regenerative stimulus that allows the thyroid to recover from postpartum thyroiditis.
E) This is the hypothyroid phase of postpartum thyroiditis; treatment with high-dose levothyroxine (3-4 mcg/kg/day) should be initiated immediately and continued for 24 months to suppress anti-TPO antibody titers, because prolonged TSH suppression reduces autoimmune activity and prevents the 25-30% progression rate to permanent hypothyroidism seen in untreated patients.

ANSWER: A

Rationale:

This question asked you to diagnose the hypothyroid phase of postpartum thyroiditis, make the treatment decision, and provide accurate long-term counseling. Option A is correct. This patient has the characteristic triphasic course of postpartum thyroiditis: unrecognized hyperthyroid phase at approximately 6 weeks postpartum (the palpitations that resolved spontaneously), followed by the current symptomatic hypothyroid phase at 5 months postpartum. Strongly positive anti-TPO antibodies confirm the autoimmune Hashimoto substrate that underlies postpartum thyroiditis. Levothyroxine is appropriate for symptomatic hypothyroidism with TSH of 12.4 mIU/L. The treatment strategy is to initiate levothyroxine for 6-12 months, then attempt a taper with TSH monitoring to determine whether the thyroid has recovered (most patients) or whether permanent hypothyroidism has developed (approximately 25-30% of patients, substantially enriched in those with strongly positive anti-TPO antibodies). Honest counseling requires communicating this 25-30% permanent hypothyroidism risk — she should not be falsely reassured that she will definitely recover, nor should she be told she definitely requires lifelong treatment.

Option B: Option B is incorrect: while postpartum thyroiditis overlaps pathologically with Hashimoto thyroiditis, the clinical classification matters for counseling — postpartum thyroiditis has a recognized recovery rate of approximately 70-75%, and not all women with TSH above 10 mIU/L and positive anti-TPO antibodies require lifelong replacement; the distinction between potentially temporary postpartum thyroiditis and established chronic Hashimoto hypothyroidism has prognostic and management implications.
Option C: Option C is incorrect: the hypothyroid phase of postpartum thyroiditis is not always self-limiting within 4 weeks; it typically lasts 4-8 months; and with symptomatic hypothyroidism and TSH of 12.4 mIU/L, treatment is indicated — withholding levothyroxine from a symptomatic patient with TSH above 10 mIU/L is not appropriate management.
Option D: Option D is incorrect: levothyroxine is not contraindicated in autoimmune thyroid disease; there is no established evidence that suppressing TSH inhibits thyroid recovery from postpartum thyroiditis; exogenous levothyroxine is the standard treatment for symptomatic hypothyroidism regardless of its autoimmune etiology.
Option E: Option E is incorrect: high-dose levothyroxine to suppress anti-TPO antibody titers is not a validated treatment strategy; prolonged TSH suppression does not prevent progression to permanent hypothyroidism in postpartum thyroiditis; the dosing target is TSH normalization for symptom relief, not TSH suppression, and high doses would cause iatrogenic thyrotoxicosis.